Which has preferable earnings & valuation, DCGO or LFMD?

LifeMD has lower revenue, but higher earnings than DocGo. LifeMD is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.11 -$182.40M -$1.96 N/A LifeMD $194.05M 0.68 $14.35M -$0.05 N/A

Is DCGO or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% LifeMD 0.10% -168.23% -31.27%

Does the media favor DCGO or LFMD?

In the previous week, DocGo had 4 more articles in the media than LifeMD. MarketBeat recorded 6 mentions for DocGo and 2 mentions for LifeMD. LifeMD's average media sentiment score of 0.67 beat DocGo's score of 0.21 indicating that LifeMD is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral LifeMD 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DCGO or JYNT?

DocGo presently has a consensus target price of $2.38, indicating a potential upside of 550.68%. Given DocGo's stronger consensus rating and higher probable upside, equities research analysts plainly believe DocGo is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better valuation and earnings, DCGO or JYNT?

Joint has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.11 -$182.40M -$1.96 N/A Joint $54.90M 1.85 $2.91M $0.27 26.59

Is DCGO or JYNT more profitable?

Joint has a net margin of 6.49% compared to DocGo's net margin of -65.29%. Joint's return on equity of 12.02% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% Joint 6.49% 12.02% 3.47%

Does the media refer more to DCGO or PARK?

In the previous week, DocGo had 4 more articles in the media than Park Dental Partners. MarketBeat recorded 6 mentions for DocGo and 2 mentions for Park Dental Partners. Park Dental Partners' average media sentiment score of 1.47 beat DocGo's score of 0.21 indicating that Park Dental Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Park Dental Partners 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, DCGO or PIII?

P3 Health Partners has higher revenue and earnings than DocGo. P3 Health Partners is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.11 -$182.40M -$1.96 N/A P3 Health Partners $1.46B 0.03 -$147.95M -$33.00 N/A

Is DCGO or PIII more profitable?

P3 Health Partners has a net margin of -6.55% compared to DocGo's net margin of -65.29%. P3 Health Partners' return on equity of 0.00% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% P3 Health Partners -6.55% N/A -16.40%

Do analysts prefer PRPO or DCGO?

DocGo has a consensus price target of $2.38, indicating a potential upside of 550.68%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Precipio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Precipio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has preferable valuation & earnings, PRPO or DCGO?

Precipio has higher earnings, but lower revenue than DocGo. Precipio is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Precipio $24.05M 1.79 -$360K -$0.64 N/A DocGo $322.20M 0.11 -$182.40M -$1.96 N/A

Is PRPO or DCGO more profitable?

Precipio has a net margin of -4.47% compared to DocGo's net margin of -65.29%. Precipio's return on equity of -8.49% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets Precipio -4.47% -8.49% -5.75% DocGo -65.29% -40.42% -24.81%

Does the media prefer PRPO or DCGO?

In the previous week, DocGo had 4 more articles in the media than Precipio. MarketBeat recorded 6 mentions for DocGo and 2 mentions for Precipio. Precipio's average media sentiment score of 0.37 beat DocGo's score of 0.21 indicating that Precipio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Precipio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DocGo 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

DocGo (DCGO) Competitors

$0.37 +0.00 (+1.10%)

As of 10:56 AM Eastern

Compare

DCGO vs. LFMD, JYNT, PARK, PIII, and PRPO

Should you buy DocGo stock or one of its competitors? DocGo's main competitors and comparable companies include LifeMD (LFMD), Joint (JYNT), Park Dental Partners (PARK), P3 Health Partners (PIII), and Precipio (PRPO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does DocGo compare to LifeMD?

DocGo (NASDAQ:DCGO) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

LifeMD has lower revenue, but higher earnings than DocGo. LifeMD is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A
LifeMD	$194.05M	0.68	$14.35M	-$0.05	N/A

56.4% of DocGo shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 5.1% of DocGo shares are owned by insiders. Comparatively, 17.2% of LifeMD shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

DocGo has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, LifeMD has a beta of 1.99, suggesting that its share price is 99% more volatile than the broader market.

LifeMD has a net margin of 0.10% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
LifeMD	0.10%	-168.23%	-31.27%

DocGo currently has a consensus price target of $2.38, suggesting a potential upside of 550.68%. LifeMD has a consensus price target of $7.57, suggesting a potential upside of 178.36%. Given DocGo's higher probable upside, equities analysts clearly believe DocGo is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, DocGo had 4 more articles in the media than LifeMD. MarketBeat recorded 6 mentions for DocGo and 2 mentions for LifeMD. LifeMD's average media sentiment score of 0.67 beat DocGo's score of 0.21 indicating that LifeMD is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LifeMD	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

LifeMD beats DocGo on 9 of the 16 factors compared between the two stocks.

How does DocGo compare to Joint?

DocGo (NASDAQ:DCGO) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

DocGo has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market. Comparatively, Joint has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

Joint has a net margin of 6.49% compared to DocGo's net margin of -65.29%. Joint's return on equity of 12.02% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
Joint	6.49%	12.02%	3.47%

In the previous week, DocGo had 6 more articles in the media than Joint. MarketBeat recorded 6 mentions for DocGo and 0 mentions for Joint. DocGo's average media sentiment score of 0.21 beat Joint's score of 0.00 indicating that DocGo is being referred to more favorably in the media.

Company	Overall Sentiment
DocGo	Neutral
Joint	Neutral

Joint has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A
Joint	$54.90M	1.85	$2.91M	$0.27	26.59

56.4% of DocGo shares are held by institutional investors. Comparatively, 76.9% of Joint shares are held by institutional investors. 5.1% of DocGo shares are held by company insiders. Comparatively, 30.2% of Joint shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

DocGo presently has a consensus target price of $2.38, indicating a potential upside of 550.68%. Given DocGo's stronger consensus rating and higher probable upside, equities research analysts plainly believe DocGo is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Joint beats DocGo on 10 of the 16 factors compared between the two stocks.

How does DocGo compare to Park Dental Partners?

DocGo (NASDAQ:DCGO) and Park Dental Partners (NASDAQ:PARK) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

In the previous week, DocGo had 4 more articles in the media than Park Dental Partners. MarketBeat recorded 6 mentions for DocGo and 2 mentions for Park Dental Partners. Park Dental Partners' average media sentiment score of 1.47 beat DocGo's score of 0.21 indicating that Park Dental Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Park Dental Partners	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.4% of DocGo shares are held by institutional investors. 5.1% of DocGo shares are held by company insiders. Comparatively, 10.6% of Park Dental Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Park Dental Partners has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Park Dental Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A
Park Dental Partners	$244.49M	0.41	-$360K	$1.05	20.09

Park Dental Partners has a net margin of 0.00% compared to DocGo's net margin of -65.29%. Park Dental Partners' return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
Park Dental Partners	N/A	N/A	N/A

DocGo currently has a consensus price target of $2.38, suggesting a potential upside of 550.68%. Park Dental Partners has a consensus price target of $28.50, suggesting a potential upside of 35.14%. Given DocGo's higher probable upside, analysts clearly believe DocGo is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Park Dental Partners beats DocGo on 11 of the 16 factors compared between the two stocks.

How does DocGo compare to P3 Health Partners?

DocGo (NASDAQ:DCGO) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

DocGo has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market.

56.4% of DocGo shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 5.1% of DocGo shares are owned by insiders. Comparatively, 10.9% of P3 Health Partners shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

P3 Health Partners has a net margin of -6.55% compared to DocGo's net margin of -65.29%. P3 Health Partners' return on equity of 0.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
P3 Health Partners	-6.55%	N/A	-16.40%

DocGo presently has a consensus target price of $2.38, suggesting a potential upside of 550.68%. P3 Health Partners has a consensus target price of $17.00, suggesting a potential upside of 175.53%. Given DocGo's stronger consensus rating and higher possible upside, analysts clearly believe DocGo is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, DocGo had 6 more articles in the media than P3 Health Partners. MarketBeat recorded 6 mentions for DocGo and 0 mentions for P3 Health Partners. DocGo's average media sentiment score of 0.21 beat P3 Health Partners' score of 0.00 indicating that DocGo is being referred to more favorably in the media.

Company	Overall Sentiment
DocGo	Neutral
P3 Health Partners	Neutral

P3 Health Partners has higher revenue and earnings than DocGo. P3 Health Partners is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A
P3 Health Partners	$1.46B	0.03	-$147.95M	-$33.00	N/A

Summary

DocGo beats P3 Health Partners on 9 of the 16 factors compared between the two stocks.

How does DocGo compare to Precipio?

Precipio (NASDAQ:PRPO) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Precipio has higher earnings, but lower revenue than DocGo. Precipio is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precipio	$24.05M	1.79	-$360K	-$0.64	N/A
DocGo	$322.20M	0.11	-$182.40M	-$1.96	N/A

10.5% of Precipio shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 16.6% of Precipio shares are owned by insiders. Comparatively, 5.1% of DocGo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Precipio has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, DocGo has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Precipio has a net margin of -4.47% compared to DocGo's net margin of -65.29%. Precipio's return on equity of -8.49% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
DocGo	-65.29%	-40.42%	-24.81%

In the previous week, DocGo had 4 more articles in the media than Precipio. MarketBeat recorded 6 mentions for DocGo and 2 mentions for Precipio. Precipio's average media sentiment score of 0.37 beat DocGo's score of 0.21 indicating that Precipio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Precipio	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
DocGo	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DocGo has a consensus price target of $2.38, indicating a potential upside of 550.68%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Precipio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Precipio beats DocGo on 9 of the 16 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$36.51M	$9.86B	$7.21B	$13.45B
Dividend Yield	N/A	2.61%	2.54%	17.38%
P/E Ratio	-0.19	34.50	274.11	26.40
Price / Sales	0.11	4.79	598.93	87.11
Price / Cash	6.68	22.82	27.22	34.70
Price / Book	0.29	5.22	11.07	6.43
Net Income	-$182.40M	$315.68M	$3.49B	$381.07M
7 Day Performance	0.27%	-0.24%	-1.23%	0.04%
1 Month Performance	-8.37%	-1.97%	-5.90%	-4.20%
1 Year Performance	-70.24%	10.26%	7.19%	2.03%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	2.8378 of 5 stars	$0.37 +1.1%	$2.38 +543.6%	-71.3%	$36.51M	$322.20M	N/A	3,568	Gap Up
LFMD LifeMD	3.1973 of 5 stars	$2.74 -3.9%	$7.57 +176.3%	-61.0%	$132.07M	$194.05M	N/A	384	Positive News
JYNT Joint	1.5905 of 5 stars	$7.28 -2.5%	N/A	-20.9%	$105.65M	$58.55M	26.96	330
PARK Park Dental Partners	4.0972 of 5 stars	$19.84 -1.3%	$28.50 +43.6%	N/A	$94.34M	$251.37M	18.90	1,212	Positive News Gap Down
PIII P3 Health Partners	2.0181 of 5 stars	$6.36 +1.4%	$17.00 +167.3%	-28.7%	$46.17M	$1.46B	N/A	320

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors